CAT

913.76

-0.09%↓

330.41

+2.55%↑

GEV.US

916.7

-1.47%↓

RTX

181.31

+1.59%↑

214.47

-0.59%↓

CAT

913.76

-0.09%↓

330.41

+2.55%↑

GEV.US

916.7

-1.47%↓

RTX

181.31

+1.59%↑

214.47

-0.59%↓

CAT

913.76

-0.09%↓

330.41

+2.55%↑

GEV.US

916.7

-1.47%↓

RTX

181.31

+1.59%↑

214.47

-0.59%↓

CAT

913.76

-0.09%↓

330.41

+2.55%↑

GEV.US

916.7

-1.47%↓

RTX

181.31

+1.59%↑

214.47

-0.59%↓

CAT

913.76

-0.09%↓

330.41

+2.55%↑

GEV.US

916.7

-1.47%↓

RTX

181.31

+1.59%↑

214.47

-0.59%↓

Accueil・Liste d'Actions・Ocugen Inc

Ocugen Inc

Fermé

1.22 -2.4

Acheter Vendre

Résumé

Variation du prix de l'action

24h

Actuel

Min

1.22

Max

1.3

Chiffres clés
By Trading Economics
Revenu	-1.5M -19M
Ventes	1.7M 1.5M
BPA	-0.06
Marge bénéficiaire	-1,250.946
Employés	116
EBITDA	-987K -17M

Recommandations
By TipRanks
Recommandations	Achat Fort
Prévisions sur 12 Mois	+807.14% upside

Dividendes
By Dow Jones
Prochains Résultats	31 juil. 2026

Statistiques du Marché
By TradingEconomics
Capitalisation Boursière	-162M 464M
Ouverture précédente	3.62
Clôture précédente	1.22

Ocugen Inc Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

9 juin 2026, 23:49 UTC

Market Talk

Nikkei May Fall Following Tech Stock Declines on Wall Street -- Market Talk

9 juin 2026, 23:45 UTC

Acquisitions, Fusions, Rachats

Correct: Sigma Healthcare: Has Engaged in Preliminary Discussions in Boots Sale Process

9 juin 2026, 23:44 UTC

Acquisitions, Fusions, Rachats

Sigma Healthcare Says No Certainty That Any Transaction Will Eventuate

9 juin 2026, 23:44 UTC

Acquisitions, Fusions, Rachats

Sigma Healthcare: Continuously Reviews Opportunities to Create Value For Shareholders

9 juin 2026, 23:43 UTC

Acquisitions, Fusions, Rachats

Sigma Healthcare: Has Engaged in Preliminary Discussions to Sell Boots

9 juin 2026, 23:35 UTC

Market Talk

Oil Rises on Escalating Supply Disruption Concerns -- Market Talk

9 juin 2026, 22:06 UTC

Acquisitions, Fusions, Rachats

Samsung: Element Has Expanded Rapidly Since 2022 Launch of AVITI

9 juin 2026, 22:05 UTC

Acquisitions, Fusions, Rachats

Samsung: Element to Speed Commercialization of Gene-Sequencing Products

9 juin 2026, 22:05 UTC

Acquisitions, Fusions, Rachats

Samsung: Additional Investment Makes It Largest Shareholder in Element

9 juin 2026, 22:05 UTC

Acquisitions, Fusions, Rachats

Samsung Electronics Raises Stake in Element Biosciences With $175 Million Investment

9 juin 2026, 20:51 UTC

Résultats

Micron, Marvell, Super Micro, Coherent, Smucker, and More Stocks That Explain Today's Market -- Barrons.com

9 juin 2026, 20:50 UTC

Market Talk

Financial Services Roundup: Market Talk

9 juin 2026, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

9 juin 2026, 20:09 UTC

Market Talk

Cryptocurrency Traders Look for Bitcoin Bottom -- Market Talk

9 juin 2026, 19:36 UTC

Market Talk

Cattle Climbs as Crude Oil Falls -- Market Talk

9 juin 2026, 19:32 UTC

Market Talk

Barclays Oil Price Outlook Contingent on Hormuz Reopening -- Market Talk

9 juin 2026, 19:25 UTC

Market Talk

U.S. Natural Gas Futures Slip in Rangebound Trade -- Market Talk

9 juin 2026, 19:00 UTC

Market Talk

Oil Settles Lower on Continued Hopes for Middle East Deal -- Market Talk

9 juin 2026, 18:52 UTC

Acquisitions, Fusions, Rachats

Warner Bros. Stock Hits a Low. Its Paramount Merger Return Is Getting Buzz. -- Barrons.com

9 juin 2026, 18:47 UTC

Market Talk

No World Cup Inflation Seen So Far in Mexico -- Market Talk

9 juin 2026, 18:37 UTC

Market Talk

Canada's Cooling Trade With the U.S. -- Market Talk

9 juin 2026, 18:27 UTC

Market Talk

Precious Metals Lower as Trump Vows Military Response -- Market Talk

9 juin 2026, 17:35 UTC

Market Talk

Treasury Yields, Dollar Briefly Rise on Trump's Iran Retaliation Threat -- Market Talk

9 juin 2026, 17:30 UTC

Market Talk

Trump Post on Apache Helicopter Causes Brief Spike in Oil -- Market Talk

9 juin 2026, 16:34 UTC

Market Talk

Cryptocurrency Weakness Follows Selling in Equities -- Market Talk

9 juin 2026, 16:20 UTC

Market Talk

Financial Services Roundup: Market Talk

9 juin 2026, 16:20 UTC

Market Talk

Basic Materials Roundup: Market Talk

9 juin 2026, 16:20 UTC

Market Talk

Acquisitions, Fusions, Rachats

Health Care Roundup: Market Talk

9 juin 2026, 15:28 UTC

Market Talk

Gold Futures Fall Further as Rate Fears Prevail -- Market Talk

9 juin 2026, 15:25 UTC

Market Talk

Oil Extends Losses, Falling More Than 3.5% -- Market Talk

Comparaison

Variation de prix

Ocugen Inc prévision

Objectif de Prix

By TipRanks

807.14% hausse

Prévisions sur 12 Mois

Moyen 11.43 USD 807.14%

Haut 22 USD

Bas 7 USD

Basé sur 7 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Achat Fort

7 ratings

Achat

Maintien

Vente

Basé sur 7 qui ont noté l'action Microsoft Corp. au cours des 3 derniers mois.

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

À Propos Ocugen Inc

Ocugen, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve patients' health. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, currently under Phase 3 trials for the treatment of retinitis pigmentosa and Phase 1/2 trials for the treatment of leber congenital amaurosis; OCU410, a gene therapy under phase 1/2 for the treatment of dry age-related macular degeneration (AMD); and OCU410ST, a gene therapy under phase 1/2 for the treatment of Stargardt disease. It is also involved in the development of OCU200, a novel fusion protein that is in preclinical development stage for the treatment of diabetic macular edema, diabetic retinopathy, and wet age-related macular degeneration; and NeoCart, an autologous chondrocyte-derived neocartilage, currently under Phase 3 studies indicated for the repair of knee cartilage injuries in adult. In addition, the company is developing OCU500, a COVID-19 vaccine; OCU510, a seasonal quadrivalent flu vaccine; and OCU520, a combination quadrivalent seasonal flu and COVID-19 vaccine. It has collaboration agreements with National Institute of Allergy and Infectious Diseases for early clinical studies for the OCU500 program; and a strategic partnership with CanSino Biologics Inc. for manufacturing its modifier gene therapy pipeline product candidates. The company was founded in 2013 and is headquartered in Malvern, Pennsylvania.